Phase 1 Study of Everolimus in Combination With Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Everolimus (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- 16 Mar 2017 Status changed from suspended to recruiting.
- 08 Feb 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 07 Jan 2016 Planned initiation date changed from 1 Sep 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.